Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1951 1
1964 1
1965 1
1972 1
1975 1
1987 1
1997 1
1998 2
1999 2
2002 1
2004 1
2009 2
2010 1
2012 1
2013 1
2014 2
2015 1
2016 5
2017 3
2018 3
2019 3
2020 5
2021 4
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Lipsyc-Sharf M, de Bruin EC, Santos K, McEwen R, Stetson D, Patel A, Kirkner GJ, Hughes ME, Tolaney SM, Partridge AH, Krop IE, Knape C, Feger U, Marsico G, Howarth K, Winer EP, Lin NU, Parsons HA. Lipsyc-Sharf M, et al. Among authors: mcewen r. J Clin Oncol. 2022 Aug 1;40(22):2408-2419. doi: 10.1200/JCO.22.00908. Epub 2022 Jun 4. J Clin Oncol. 2022. PMID: 35658506 Free PMC article.
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel L, Ferrero JM, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R, Stetson D, Dougherty B, Sarker SJ, Prendergast A, McLaughlin-Callan M, Burgess M, Lawrence C, Cartwright H, Mousa K, Turner NC. Schmid P, et al. Among authors: mcewen r. J Clin Oncol. 2020 Feb 10;38(5):423-433. doi: 10.1200/JCO.19.00368. Epub 2019 Dec 16. J Clin Oncol. 2020. PMID: 31841354 Free article. Clinical Trial.
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, Biganzoli L, Ambrose HJ, Ashton J, Barnicle A, Cashell DD, Corcoran C, de Bruin EC, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Pass M, Rowlands V, Schiavon G, Banerji U, Scaltriti M, Taylor BS, Chandarlapaty S, Baselga J, Hyman DM. Smyth LM, et al. Among authors: mcewen r. Clin Cancer Res. 2020 Aug 1;26(15):3947-3957. doi: 10.1158/1078-0432.CCR-19-3953. Epub 2020 Apr 20. Clin Cancer Res. 2020. PMID: 32312891 Free PMC article. Clinical Trial.
Antibiotic review kit for hospitals (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial.
Llewelyn MJ, Budgell EP, Laskawiec-Szkonter M, Cross ELA, Alexander R, Bond S, Coles P, Conlon-Bingham G, Dymond S, Evans M, Fok R, Frost KJ, Garcia-Arias V, Glass S, Gormley C, Gray K, Hamson C, Harvey D, Hills T, Iyer S, Johnson A, Jones N, Kang P, Kiapi G, Mack D, Makanga C, Mawer D, McCullagh B, Mirfenderesky M, McEwen R, Nag S, Nagar A, Northfield J, O'Driscoll J, Pegden A, Porter R, Powell N, Price D, Sheridan E, Slatter M, Stewart B, Watson C, Weichert I, Sivyer K, Wordsworth S, Quaddy J, Santillo M, Krusche A, Roope LSJ, Mowbray F, Hand KS, Dobson M, Crook DW, Vaughan L, Hopkins S, Yardley L, Peto TEA, Walker AS. Llewelyn MJ, et al. Among authors: mcewen r. Lancet Infect Dis. 2023 Feb;23(2):207-221. doi: 10.1016/S1473-3099(22)00508-4. Epub 2022 Oct 4. Lancet Infect Dis. 2023. PMID: 36206793 Free article. Clinical Trial.
Defining actionable mutations for oncology therapeutic development.
Carr TH, McEwen R, Dougherty B, Johnson JH, Dry JR, Lai Z, Ghazoui Z, Laing NM, Hodgson DR, Cruzalegui F, Hollingsworth SJ, Barrett JC. Carr TH, et al. Among authors: mcewen r. Nat Rev Cancer. 2016 Apr 26;16(5):319-29. doi: 10.1038/nrc.2016.35. Nat Rev Cancer. 2016. PMID: 27112209 Review.
Harris WE, McEwen RA. Harris WE, et al. Among authors: mcewen ra. J Ga Dent Assoc. 1975 Spring;48(4):10-2. J Ga Dent Assoc. 1975. PMID: 800842 No abstract available.
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Dunn S, Eberlein C, Yu J, Gris-Oliver A, Ong SH, Yelland U, Cureton N, Staniszewska A, McEwen R, Fox M, Pilling J, Hopcroft P, Coker EA, Jaaks P, Garnett MJ, Isherwood B, Serra V, Davies BR, Barry ST, Lynch JT, Yusa K. Dunn S, et al. Among authors: mcewen r. Oncogene. 2022 Nov;41(46):5046-5060. doi: 10.1038/s41388-022-02482-9. Epub 2022 Oct 14. Oncogene. 2022. PMID: 36241868 Free PMC article.
47 results